Avoro Capital Advisors LLC 13D and 13G filings for Xenon Pharmaceuticals Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 09:12 am Purchase | 2023-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE | Avoro Capital Advisors LLC | 5,666,666 7.700% | 766,666 (+15.65%) | Filing |
| 2023-02-14 09:41 am Sale | 2022-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE | Avoro Capital Advisors LLC | 4,900,000 7.800% | -85,000 (-1.71%) | Filing |
| 2022-02-11 10:00 am Purchase | 2021-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE | Avoro Capital Advisors LLC | 4,985,000 9.700% | 2,185,000 (+78.04%) | Filing |
| 2021-02-12 08:14 am Purchase | 2020-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE | Avoro Capital Advisors LLC | 2,800,000 8.000% | 400,000 (+16.67%) | Filing |